{"text_format":"2","workbook":"xls","n_sheets":1,"sheets":["report2"],"not_rendered":{"charts":0,"images":0,"macros":0,"external_links":1,"defined_names":1,"comments":0,"pivot_tables":0},"unopened":[],"bounds":{"document_bytes":16777216,"sheet_cells":100000,"run_cost":"one","rows_first":2000,"rows_last":500,"rows_between":2000,"halvings":0,"cell_chars":16384,"cell_head_chars":4096},"cells_cut":0,"cells_raw":0,"read":"whole","date_system":"1900","formulas":"cached_only"}

{"sheet":"report2","index":0,"n_rows":21,"n_cols":5,"rows_kept":21,"cut":false,"hidden":false,"merged":[[0,2,0,3],[0,4,0,5],[1,2,1,3],[1,4,1,5],[2,2,2,3],[3,2,3,3],[4,2,4,3],[5,2,5,3],[6,2,6,3],[7,2,7,3],[13,2,13,3],[14,2,14,3],[18,2,18,3]],"flags":["formulas_cached_only"]}
[null,"1.","Record Nr.",null,"UNINA9910465297803321"]
[null,null,"Titolo",null,"Biosimilars handbook [[electronic resource]]"]
[null,null,"Pubbl/distr/stampa",null,"[London], : SAGE, 2011"]
[null,null,"ISBN",null,"1-4462-0896-6"]
[null,null,"Edizione",null,"[2nd ed.]"]
[null,null,"Descrizione fisica",null,"1 online resource (56 p.)"]
[null,null,"Disciplina",null,"615.19 22"]
[null,null,"Soggetti",null,"Pharmaceutical biotechnology"]
[{"$nulls":4},"Pharmaceutical biotechnology industry"]
[{"$nulls":4},"Drugs - Generic substitution"]
[{"$nulls":4},"Pharmaceutical policy"]
[{"$nulls":4},"Biological products"]
[{"$nulls":4},"Electronic books."]
[null,null,"Lingua di pubblicazione",null,"Inglese"]
[null,null,"Formato",null,"Materiale a stampa"]
[null,null,null,"Livello bibliografico","Monografia"]
[null,null,null,"Note generali","Description based upon print version of record."]
[null,null,null,"Nota di bibliografia","Includes bibliographical references."]
[null,null,"Nota di contenuto",null,"\"\"Front Cover \"\"; \"\"Contents\"\"; \"\"Introduction \"\"; \"\"What this handbook covers \"\"; \"\"Whom this handbook for \"\"; \"\"Executive Summary \"\"; \"\"The importance of biosimilar medicines\"\"; \"\"The health economic benefits from biosimilar medicines\"\"; \"\"Nomenclature of biopharmaceuticals, including biosimilar medicines\"\"; \"\"List of European Commission-approved biosimilar medicines\"\"; \"\"The science and technology of biosimilar medicines\"\"; \"\"Regulation of biosimilar medicines\"\"; \"\"Introduction of biosimilar medicines into clinical practice\"\"; \"\"The future and evolving landscape of biosimilar medicines\"\""]
[{"$nulls":4},"\"\"Further information\"\"\"\"Contributors\"\"; \"\"Glossary\"\"; \"\"Acronyms and  Abbreviations\"\"; \"\"Appendix\"\"; \"\"Back Cover\"\""]
[null,null,null,"Sommario/riassunto","This handbook aims to provide updated information on the current progress of biosimilar medicines in the European Union (EU). The first edition of this short guide to biosimilar medicines was published in 2007. At the time of first publication, only 5 biosimilar medicines had been approved in Europe, and both the legislation and concepts for these products were very new. Now the situation has developed and changed, as will be described herein, and the clinical and health economic benefits offered by biosimilar medicines to patients, clinicians and healthcare providers are considerably clearer."]